UCB/€UCB
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About UCB
UCB SA, founded in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. The company specializes in the research, development, and commercialization of innovative therapies primarily for the treatment of neurological and immunological disorders. Operating in the healthcare sector, UCB is dedicated to advancing science and addressing unmet medical needs for patients worldwide.
Ticker
€UCB
Sector
Primary listing
BSE
Industry
Pharmaceuticals
Headquarters
Employees
9,215
ISIN
BE0003739530
Website
UCB Metrics
BasicAdvanced
€32B
29.94
€5.61
0.34
€0.97
0.58%
Price and volume
Market cap
€32B
Beta
0.34
52-week high
€198.95
52-week low
€129.35
Average daily volume
231K
Dividend rate
€0.97
Financial strength
Current ratio
1.357
Quick ratio
0.871
Long term debt to equity
29.544
Total debt to equity
30.172
Dividend payout ratio (TTM)
24.32%
Interest coverage (TTM)
5.19%
Profitability
EBITDA (TTM)
1,477
Gross margin (TTM)
71.52%
Net profit margin (TTM)
17.31%
Operating margin (TTM)
13.78%
Effective tax rate (TTM)
8.43%
Revenue per employee (TTM)
€670,000
Management effectiveness
Return on assets (TTM)
3.22%
Return on equity (TTM)
11.21%
Valuation
Price to earnings (TTM)
29.936
Price to revenue (TTM)
5.182
Price to book
3.16
Price to tangible book (TTM)
65.42
Price to free cash flow (TTM)
34.652
Free cash flow yield (TTM)
2.89%
Free cash flow per share (TTM)
484.25%
Dividend yield (TTM)
0.58%
Forward dividend yield
0.58%
Growth
Revenue change (TTM)
18.72%
Earnings per share change (TTM)
218.48%
3-year revenue growth (CAGR)
2.12%
10-year revenue growth (CAGR)
6.29%
3-year earnings per share growth (CAGR)
0.91%
10-year earnings per share growth (CAGR)
17.49%
3-year dividend per share growth (CAGR)
2.26%
10-year dividend per share growth (CAGR)
2.75%
What the Analysts think about UCB
Analyst ratings (Buy, Hold, Sell) for UCB stock.
Bulls say / Bears say
UCB's 2023 revenue exceeded expectations, reaching €5.25 billion, driven by strong sales of Evenity and Cimzia. (reuters.com)
Deutsche Bank raised UCB's price target to €200, citing potential for Bimzelx to surpass €5 billion in sales and a projected EBITDA CAGR of 26% from 2024 to 2027. (investing.com)
UCB's strategic focus on expanding its product offerings in key therapeutic areas positions the company for robust growth. (investing.com)
UCB's revenue showed a slight decline of 4.87% over the last twelve months as of Q1 2023, indicating potential challenges in maintaining consistent growth. (investing.com)
The company's net profit margin stands at 6.56%, which may be considered low compared to industry peers, potentially impacting investor confidence. (strike.market)
UCB's debt-to-assets ratio increased to 42.24% as of December 2023, suggesting a higher reliance on debt financing, which could pose risks if not managed effectively. (strike.market)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
UCB Financial Performance
Revenues and expenses
UCB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UCB stock?
UCB (UCB) has a market cap of €32B as of July 01, 2025.
What is the P/E ratio for UCB stock?
The price to earnings (P/E) ratio for UCB (UCB) stock is 29.94 as of July 01, 2025.
Does UCB stock pay dividends?
Yes, the UCB (UCB) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is €0.973 and the yield is 0.58%. UCB has a payout ratio of 24.32% on a trailing twelve-month basis.
When is the next UCB dividend payment date?
The next UCB (UCB) dividend payment date is unconfirmed.
What is the beta indicator for UCB?
UCB (UCB) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.